Integrating Recent Advances into the Management of Metastatic Hormone-Sensitive Prostate Cancer
A CME/MOC-Accredited Interactive Grand Rounds Series
Research To Practice (RTP) is pleased to offer hospitals and cancer centers throughout the United States the opportunity to participate in an interactive live educational activity focused on the management of prostate cancer. Each session in this regional series will feature a blend of didactic presentation, discussion of steering committee members’ treatment recommendations and follow-up audience Q&A.
If you are interested in hosting a session at your organization, please email our Meetings Department at Meetings@ResearchToPractice.com or call (800) 233-6153.
Neeraj Agarwal
MD, FASCO
The Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
Faculty Medical Oncologist, Dana-Farber Cancer Institute, Co-Director, Prostate Cancer Program, Harvard Cancer Consortium
Elisabeth I Heath
MD, FACP
Mayo Clinic, Rochester, Minnesota
Chair, Department of Oncology, Professor of Oncology
Rana R McKay
MD, FASCO
Moores Cancer Center, University of California San Diego, San Diego, California
Professor of Medicine, Urology, and Radiation Medicine and Applied Sciences, Associate Director, Clinical Research, Co-Lead, Genitourinary Program
Scott T Tagawa
MD, MS
Weill Cornell Medicine, New York, New York
Gebroe Family Professor of Hematology-Oncology, Professor of Medicine in Urology
Meyer Cancer Center, New York, New York
Medical Director, Genitourinary Oncology Program, Leader, GU Disease Management Team
Evan Y Yu
MD
Fred Hutchinson Cancer Center, Seattle, Washington
Section Head, Medical Oncology, Clinical Research Division
Fred Hutchinson Cancer Research Consortium, Seattle, Washington
Associate Director of Clinical Research
University of Washington School of Medicine, Seattle, Washington
Professor of Medicine, Division of Hematology and Oncology, Department of Medicine
Additional faculty to be announced.
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP and Novartis.
Each 1-hour session will include 4 topic modules focused on the management of prostate cancer. Each event will employ an identical format that will include the following elements:
- Discussion of Steering Committee Members’ Treatment Recommendations
- Review of Available Clinical Research Findings
- Integration of Interactive Audience Q&A Discussion
MODULE 1 — Current Role of Androgen Receptor Pathway Inhibitors with or without Chemotherapy for Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
MODULE 2 — Use of PARP Inhibitors for mHSPC
MODULE 3 — Emerging Role of AKT Inhibition in Therapy for mHSPC
MODULE 4 — Potential Use of Radioligand Therapy in the Management of mHSPC
Each session will conclude with a 5-minute Q&A segment
Target Audience
This activity is intended for medical and radiation oncologists, urologists and other healthcare professionals involved in the diagnosis and treatment of prostate cancer.
Learning Objectives
Upon completion of this activity, participants should be able to
- Infer how various clinical and biological factors affect the selection of therapy for patients with metastatic hormone-sensitive prostate cancer (mHSPC), and design appropriate treatment plans, considering the potential benefits of treatment intensification with combination approaches.
- Evaluate the published research database supporting the FDA approvals of androgen receptor pathway inhibitors (ARPIs) alone and in combination with chemotherapy in the management of mHSPC, and apply this information in the discussion of nonresearch treatment options for patients.
- Assess available and emerging research findings with PARP inhibitors in combination with ARPIs for patients with mHSPC harboring a homologous recombination repair gene alteration, and discern how to optimally incorporate these agents into clinical management algorithms.
- Appreciate the biological rationale for targeting the PI3K/AKT/mTOR pathway in prostate cancer, and evaluate available and emerging data with novel AKT inhibitors in combination with hormonal therapy for patients with mHSPC and PTEN deficiency.
- Review available Phase III data documenting the efficacy of radioligand therapy for mHSPC, and consider the current and potential role of this strategy.
- Recall the design of ongoing clinical trials evaluating other novel agents and strategies for mHSPC, and appropriately counsel patients about availability and participation.
CE Credit
CME and ABIM MOC credit information will be provided to each participant at the conclusion of the activity.
Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
Research To Practice designates each live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of each CME activity, which includes participation in the evaluation component and a post-test, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.
American Board of Surgery (ABS) — Continuous Certification (CC)
Successful completion of each CME activity, which includes participation in the evaluation component and a post-test, enables the learner to earn up to 1 Medical Knowledge MOC point toward the CME and Self-Assessment requirement(s) of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABS credit.
Please note, this program has been specifically designed for the following ABS practice area: complex general surgical oncology.
Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.
Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Faculty disclosures will be provided.
Steering Committee
Dr Agarwal has no relevant financial relationships to disclose. The following faculty reported relevant financial relationships with ineligible entities:
Dr Heath — Advisory Committees (Personal Compensation): AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, EMD Serono Inc, Gilead Sciences Inc, Novartis, Peptone, Petauri Kinect, Pfizer Inc, Sanofi, Seagen Inc, Sumitomo Pharma America; Advisory Committees (to Institution): Janssen Biotech Inc; Consulting Agreements (Personal Compensation): Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Novartis, Sanofi; Consulting Agreements (to Institution): AstraZeneca UK Ltd, Novartis; Contracted Research (Grants): K36 Therapeutics, Novartis; Contracted Research (Research Support): Amgen Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BioXcel Therapeutics Inc, Bristol Myers Squibb, Calithera Biosciences, Caris Life Sciences, Corcept Therapeutics Inc, Corvus Pharmaceuticals, Daiichi Sankyo Inc, Eisai Inc, Exelixis Inc, Fortis Therapeutics, Gilead Sciences Inc, GSK, Harpoon Therapeutics, Infinity Pharmaceuticals Inc, iTeos Therapeutics, Janssen Research and Development, K36 Therapeutics, Merck, Mirati Therapeutics Inc, Modra Pharmaceuticals, MSD, Novartis, Oncolys Biopharma, Peloton Therapeutics Inc, a wholly-owned subsidiary of Merck & Co Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, POINT Biopharma, Roche Laboratories Inc, Seagen Inc; Presentations: Curio Science, DAVA Oncology; Speakers Bureaus: Sanofi; Steering Committees (Uncompensated): ORIC Pharmaceuticals; Travel Support: AstraZeneca UK Ltd; Nonrelevant Financial Relationships: Calibr-Skaggs Institute for Innovative Medicines, Caris Centers of Excellence for Precision Medicine Network, Digital Science Press, IDEOlogy Health, Johns Hopkins University, NCCN, PeerView Institute for Medical Education, Prostate Cancer Foundation, Prostate Cancer Research Institute, University of Michigan, Wayne State University. Dr McKay — Advisory Committees and Consulting Agreements: Ambrx, Arcus Biosciences, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Blue Earth Diagnostics, Boundless Bio, Bristol Myers Squibb, Calithera Biosciences, Caris Life Sciences, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Janssen Biotech Inc, Lilly, Merck, Myovant Sciences, Neomorph, Nimbus Therapeutics, Novartis, Pfizer Inc, Sanofi, Seagen Inc, Sorrento Therapeutics, Telix Pharmaceuticals Limited, Tempus; Contracted Research: Artera, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis Inc, Incyte Corporation, Natera Inc, Oncternal Therapeutics. Dr Tagawa — Consulting Agreements: AbbVie Inc, Abdera Therapeutics, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biohaven, Blue Earth Diagnostics, Boston Scientific Corporation, Clarity Pharmaceuticals, Convergent Therapeutics Inc, Daiichi Sankyo Inc, EMD Serono Inc, General Electric Company, Gilead Sciences Inc, Johnson & Johnson, Lantheus, Lilly, Merck, Myovant Sciences, Novartis, Pfizer Inc, Regeneron Pharmaceuticals Inc, Telix Pharmaceuticals Limited; Contracted Research: AIQ Solutions, Bayer HealthCare Pharmaceuticals, Clarity Pharmaceuticals, Gilead Sciences Inc, Janux Therapeutics, Johnson & Johnson, Lilly, Merck, Novartis, Pfizer Inc, Telix Pharmaceuticals Limited; Data and Safety Monitoring Boards/Committees: Boston Scientific Corporation, Ratio Therapeutics, Telix Pharmaceuticals Limited; Stock OPTIONS — Private Companies: Convergent Therapeutics Inc; Nonrelevant Financial Relationships: UroToday. Dr Yu — Consulting Agreements: Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Johnson & Johnson, Lantheus, Merck, Novartis, Samsung Bioepis, Tolmar; Contracted Research: Bayer HealthCare Pharmaceuticals, Blue Earth Diagnostics, Dendreon Pharmaceuticals Inc, Lantheus, Merck, Pfizer Inc, Tyra Biosciences Inc. Additional faculty to be announced.
Program Chair — Neil Love, MD, is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Catalyst Pharmaceuticals Inc, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Nuvation Bio Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Summit Therapeutics, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, and Verastem Inc.
Research To Practice CME Planning Committee Members, Staff and Reviewers
Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
Supporters
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP and Novartis.